Neogen Analyst Price Targets

Neogen Corp

NEOGNASDAQ

Trade with Public

$11.63

-0.18-1.52%

Dern. MÀJ: Oct 19, 4:30 PM

$11.74

-0.07-0.59%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Neogen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neogen (NEOG).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

1S.Buy

2Buy

1Hold

Consensus RatingMarket Outperform# Analysts4Avg. Consensus PT$13Upside to Avg. PT+7.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$12→$14
Aug 26, 2026	Piper Sandler	David Westenberg	Upgrade	Neutral→Overweight	$13→$14
Aug 3, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$11→$13
Jan 12, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$7→$10
Jan 9, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$8→$12
Dec 10, 2025	CJS Securities	Robert Labick	Upgrade	Market Perform→Market Outperform	$10
Oct 16, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$5→$7
Sep 29, 2025	CJS Securities	Robert Labick	Initiate	Market Perform	$10
Jul 29, 2025	William Blair	Brandon Vazquez	Downgrade	Outperform→Market Perform	—
Jun 30, 2025	Guggenheim	Subbu Nambi	PT Cut	Buy	$13→$10
Apr 22, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$6→$5
Apr 14, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$13→$7
Apr 10, 2025	Guggenheim	Subbu Nambi	PT Cut	Buy	$15→$13
Jan 21, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$17→$13
Dec 19, 2024	Guggenheim	Subbu Nambi	Initiate	Buy	$15
Aug 6, 2024	Piper Sandler	David Westenberg	PT Raise	Neutral	$17→$18
Apr 15, 2024	Piper Sandler	David Westenberg	PT Cut	Neutral	$19→$17
Jan 18, 2024	Piper Sandler	David Westenberg	PT Raise	Neutral	$18→$19

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Neogen, Raises Price Target to $14

Guggenheim analyst Subbu Nambi maintains Neogen (NASDAQ:NEOG) with a Buy and raises the price target from $12 to $14.

Benzinga Newsdesk

PRO
Watching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

Benzinga Newsdesk

Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Neogen will report Q1 earnings Oct. 6, with EPS forecast at 5 cents and revenue at $208.18M; analysts recently raised ratings and targets.

Avi Kapoor

PRO
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

Piper Sandler analyst David Westenberg upgrades Neogen (NASDAQ:NEOG) from Neutral to Overweight and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

Piper Sandler analyst David Westenberg reiterates Neogen (NASDAQ:NEOG) with a Neutral and raises the price target from $11 to $13.

Benzinga Newsdesk

Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Neogen Corporation (NASDAQ: NEOG) to release Q3 earnings on April 9. Analysts expect 5 cents/share, down from 10 cents last year. Stock rose 1.6% on Monday.

Avi Kapoor

Neogen Corp

Neogen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Neogen, Raises Price Target to $14

PRO
Watching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PRO
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PRO
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Neogen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Neogen, Raises Price Target to $14

PRO
Watching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PRO
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PRO
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

People Also Watch

People Also Watch

Neogen Corp

Neogen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Neogen, Raises Price Target to $14

PROWatching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PROPiper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PROPiper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Neogen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Neogen, Raises Price Target to $14

PROWatching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PROPiper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PROPiper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Neogen, Raises Price Target to $14

PRO
Watching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

PRO
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PRO
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13

PRO
Guggenheim Maintains Buy on Neogen, Raises Price Target to $14

PRO
Watching Neogen; Traders Circulate Unconfirmed Analyst Report Defending NEOG After Sell-Off, Says Product Is Third-Party Manufactured, Revenue Impact Immaterial And FDA Dialogue Ongoing

PRO
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14

PRO
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13